Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus

11Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

Background: Prospective comparative studies on the effects of various antidiabetic agents on bone metabolism are limited. This study aimed to assess changes in bone mass and biochemical bone markers in postmenopausal patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multicenter, open-label, comparative trial included 264 patients with T2DM. Patients who had received a metformin, or sulfonylurea/metformin combination (Group 1); a thiazolidinedione combination (Group 2); a dipeptidyl peptidase-4 inhibitor (gemigliptin) combination (Group 3); or an sodium-glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4) were prospectively treated for 12 months; bone mineral density (BMD) and bone turnover marker (BTM) changes were evaluated. Results: The femoral neck BMD percentage changes were -0.79%±2.86% (Group 1), -2.50%±3.08% (Group 2), -1.05%±2.74% (Group 3), and -1.24%±2.91% (Group 4) (P<0.05). The total hip BMD percentage changes were -0.57%±1.79% (Group 1), -1.74%±1.48% (Group 2), -0.75%±1.87% (Group 3), and -1.27%±1.72% (Group 4) (P<0.05). Mean serum BTM (C-terminal type 1 collagen telopeptide and procollagen type 1 amino-terminal propeptide) levels measured during the study period did not change over time or differ between groups. Conclusion: Significant bone loss in the femoral neck and total hip was associated with thiazolidinedione combination regimens. However, bone loss was not significantly associated with combination regimens including gemigliptin or empagliflozin. Caution should be exercised during treatment with antidiabetic medications that adversely affect the bone in patients with diabetes at a high risk of bone loss.

References Powered by Scopus

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025

3352Citations
N/AReaders
Get full text

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

2729Citations
N/AReaders
Get full text

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - A meta-analysis

1528Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study

6Citations
N/AReaders
Get full text

Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis

5Citations
N/AReaders
Get full text

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

2Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ha, J., Lim, Y., Kim, M. K., Kwon, H. S., Song, K. H., Ko, S. H., … Baek, K. H. (2021, August 1). Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinology and Metabolism. Korean Endocrine Society. https://doi.org/10.3803/ENM.2021.1026

Readers over time

‘21‘22‘23‘24‘2508162432

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

79%

Professor / Associate Prof. 2

14%

Researcher 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

39%

Nursing and Health Professions 4

22%

Biochemistry, Genetics and Molecular Bi... 4

22%

Sports and Recreations 3

17%

Save time finding and organizing research with Mendeley

Sign up for free
0